WaveMan
WaveMan · Company
ABSI · Absci Corp
> Search tickers & screens ⌘K
LIVE
← All companies

ABSI Absci (ABSI) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Services-commercial physical & biological research · CIK 0001672688
Quote by TradingView
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
126
13F, latest reported quarter

What the filings say about ABSI

Insiders, 180 days
+$349.6K net bought
2 buyers

Absci insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Absci Corp insiders bought a net $349.6K of stock across 31 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-27.

Insider
Filed
Shares
Value
Since filing
Szela Mary T
Director
BUY
2026-07-06 SECtraded 2026-06-30
12,900
$148.9K
-16.6%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 60.6% of the 21,300 shares held after it.
  • No other insider bought within 30 days.
  • 126 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Szela Mary T bought about $148.9K of ABSI on Jun 30, 2026; 126 funds added in the latest 13F quarter.
Pangalos Menelas N
Director
BUY
2026-05-13 SEC
37,453
$200.7K
+70.6%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Feb 27, 2026.
  • +79.2% median (+79.2% mean) 90-day return after 2 previous buys.
  • The trade is 16.1% of the 232,308 shares held after it.
  • No other insider bought within 30 days.
  • 126 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Pangalos Menelas N bought about $200.7K of ABSI on May 13, 2026; 126 funds added in the latest 13F quarter.
Busch Andreas
Chief Innovation Officer
BUY
2026-03-16 SECtraded 2026-03-12
100,000
$229.0K
+211.9%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jul 28, 2025.
  • The trade is 23.7% of the 421,446 shares held after it.
  • 1 other insider bought within 30 days.
  • 126 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Innovation Officer Busch Andreas bought about $229.0K of ABSI on Mar 12, 2026; 1 other insider bought within 30 days and 126 funds added in the latest 13F quarter.
Pangalos Menelas N
Director
BUY
2026-03-03 SECtraded 2026-02-27
75,095
$205.8K
+255.3%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Sep 22, 2025.
  • The trade is 39.7% of the 189,055 shares held after it.
  • 1 other insider bought within 30 days.
  • 126 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Pangalos Menelas N bought about $205.8K of ABSI on Feb 27, 2026; 1 other insider bought within 30 days and 126 funds added in the latest 13F quarter.
McClain Sean
Chief Executive Officer
SELL
2026-02-04 SECtraded 2026-02-02
26,761
$80.0K
+273.5%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Jan 19, 2022.
  • -17.8% median (-17.8% mean) 90-day return after 2 previous buys.
  • The trade is 0.3% of the 8,334,567 shares held after it.
  • 1 other insider sold within 30 days.
  • 126 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer McClain Sean sold about $80.0K of ABSI on Feb 2, 2026, the largest insider sale at the company since 2024; 1 other insider sold within 30 days and 126 funds added in the latest 13F quarter.
31 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 26 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$349.6K over 180 days
more than 83% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
126 funds bought in last quarter
more than 77% of Pharma & Biotech
Revenue
-38.2% year over year
below 76% of Pharma & Biotech
Margin
-4113.7% net margin
below 95% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
22.9% of the float short (float per yahoo 2026-10-26) · 7.5 days to cover · settled 2026-09-30
more than 96% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ABSI

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+120.5%12M
-46%+26%+99%+171%2025-102025-122026-022026-042026-062026-082026-10 2026-03-12 · Busch Andreas bought $229.0K2026-02-27 · Pangalos Menelas N bought $205.8K2026-05-13 · Pangalos Menelas N bought $200.7K2026-06-30 · Szela Mary T bought $148.9K2025-12-05 · VAN HOUTEN FRANS bought $148.8K2026-02-02 · McClain Sean sold $80.0K2026-02-02 · Jonasson Zachariah sold $52.3K
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ABSI: institutional holders (13F)

13F holdings, latest reported quarter
FMR LLC
25,410,048 sh
$294.5M
ARK Investment Management LLC
12,925,271 sh
$149.8M
BlackRock, Inc.
12,175,302 sh
$141.1M
STATE STREET CORP
8,097,308 sh
$93.8M
AMERIPRISE FINANCIAL INC
6,991,763 sh
$81.0M

Congress trades in ABSI

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ABSI planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

ABSI mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
ARK Genomic Revolution ETF
$80.0M position · as of 2026-07-31
5.1%
ALGER SMALL CAP GROWTH FUND
$5.0M position · as of 2026-07-31
2.5%
Alger Small Cap Growth Portfolio
$3.9M position · as of 2026-06-30
2.4%
ALGER SMALL CAP GROWTH INSTITUTIONAL FUND
$1.5M position · as of 2026-07-31
1.8%
Columbia Acorn Fund
$33.5M position · as of 2026-06-30
1.2%
Columbia Variable Portfolio - Acorn Fund
$6.4M position · as of 2026-06-30
1.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $349.6K bought by insiders over 180 days, 126 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ABSI financials

Revenue growth
-38.2%
XBRL, annual
Net margin
-4113.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$1.6M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-7,756%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$109.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.02x
long-term debt only, 2024-12-31 (18 months older than the period end); equity 2026-06-30
Cash flow to debt
-27.09x
TTM operating cash flow over long-term debt only, 2024-12-31 (18 months older than the period end)
Return on equity
-57.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-50.6%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-59.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$1.5B
market value at close 2026-10-26 on 2026-07-31 shares, plus long-term debt only, 2024-12-31 (18 months older than the period end), minus cash 2026-06-30
FCF yield
-6.7%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$2.8M$4.5M$5.7M$5.7M
Operating income-$120.3M-$108.9M-$115.5M-$106.8M
Net income-$115.2M-$103.1M-$110.6M-$104.9M
EPS (diluted)-0.84-0.94-1.20-1.15
Operating cash flow-$92.9M-$72.4M-$64.6M-$81.3M
Cash$20.0M$41.2M$72.4M$60.0M
Long-term debtn/a$4.0M$7.9M$10.9M
SEC XBRL, fiscal years, as known on 2026-10-27

ABSI Stock Sonar score 6/7 axes

Find similar shapesCompare

ABSI ranks highest on insider conviction (82nd percentile) and institutional and government (77th), and lowest on risk and compliance (15th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
45
Inputs
  • Return on equity-57.7% · 50 pct, sector of 545
  • Return on assets-50.6% · 44 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-59.0% · 43 pct, sector of 576
Financial health
45
Inputs
  • Debt to equity0.02x · 74 pct, sector of 352
  • Cash flow to debt-27.09x · 17 pct, sector of 371
Growth
24
Inputs
  • Revenue growth, YoY-38.2% · 24 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
82
Inputs
  • Net Form 4 buying (codes P and S), 180d$350K · 83 pct, sector of 428
  • Insider buyers, 180d2 · 81 pct, sector of 437
Institutional and government
77
Inputs
  • Funds adding, latest quarter126 · 77 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
15
Inputs
  • Short interest, % of float+22.9% · 11 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+18.5% · 20 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ABSI filings, in plain words

Are Absci insiders buying or selling ABSI?

In the 180 days to 2026-10-27, Absci insiders were net buyers, a net $349.6K across purchases and sales reported on Form 4, by 2 buyers.

Read the full summary

In the 180 days to 2026-10-27, Absci insiders were net buyers of ABSI, a net $349.6K across purchases and sales reported on Form 4 by 2 buyers. Each figure is counted from SEC and House filings as of 2026-10-27, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies